Navigation Links
Industry Veteran Katrine Bosley Joins Genocea Biosciences' Board Of Directors

CAMBRIDGE, Mass., March 12, 2013 /PRNewswire/ -- Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has added Katrine Bosley , a proven biotechnology industry leader, as an independent director.

"Katrine brings a unique and important perspective to our board as we continue to advance our lead programs within this new class of vaccines," said Chip Clark , CEO of Genocea. "The breadth of her experience in creating strategic and business development value will be tremendously important as Genocea develops."

Genocea's lead programs include GEN-003, a therapeutic vaccine candidate designed to treat people infected with Herpes Simplex Virus type 2 (HSV-2), and GEN-004, a vaccine candidate to prevent infections caused by Streptococcus pneumoniae. Genocea has fully enrolled its Phase 1/2a study of GEN-003 and expects to report preliminary data in the second half of 2013. The company also anticipates beginning clinical trials in late 2013 for GEN-004.

"Genocea's ability to create T cell-directed vaccines is pioneering and has the potential to significantly extend the range of diseases that can be addressed by vaccines," said Bosley. "The team at Genocea is developing product candidates that tackle tough, important medical problems. This combination of innovation and execution makes Genocea a uniquely exciting company."

Katrine was the CEO of Avila Therapeutics and led the company to establish several strategic alliances prior to its acquisition by Celgene in 2012. Before Avila, Katrine was Vice President, Business Development at Adnexus Therapeutics (acquired by Bristol-Myers Squibb). She joined Adnexus from Biogen Idec where she held roles in business development, commercial operations, and portfolio strategy in the U.S. and Europe and led the in-licensing of Tysabri® (natalizumab) among a number of other transactions. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners.

About Genocea Biosciences
Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify and employ T cell antigens using ATLAS™, its proprietary technology platform, which mimics human T cell immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them.

Genocea's pipeline of novel T cell vaccines includes GEN-003, a clinical-stage program in Herpes Simplex Virus type 2 (HSV-2) therapy, and GEN-004 for Pneumococcus, as well as earlier-stage programs for Chlamydia, HSV-2 prophylaxis, and malaria.

For more information, please visit the company's website at

For information contact:
Jessica Rowlands
Feinstein Kean Healthcare

SOURCE Genocea Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rutgers Business Schools Pharma Industry Scholars Program offers students distinct advantages to help boost careers in healthcare industry
2. Frost & Sullivan: Government Support Vital to Encourage Venture Capital Investments in the North American Healthcare Industry
3. DATATRAK Participates in March Industry Events
4. TCS Named as a Leader in Life Science Drug Safety Services by Leading Industry Research Firm
5. HIMMS 2013 - Santa Rosa Holdings Hosts Healthcare Industry Leaders Tommy Thompson and Fred Brown March 5th in New Orleans
6. Medical Marijuana Inc Reviews State of the Industry and Prospects for Future Growth
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. UBM Launches, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
9. Medbox Featured in Huffington Post Report on the Legal Marijuana Industry
10. Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
11. Global Trends in the Medical Devices Industry
Post Your Comments:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):